Abstracts Archive - Page 1251 of 2607 - ACR Meeting Abstracts

Abstract Number: 970 • 2018 ACR/ARHP Annual Meeting
Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Daniel J. Wallace¹, Richard Furie², Yoshiya Tanaka³, Kenneth C. Kalunian⁴, Marta Mosca⁵, Michelle Petri⁶, Thomas Dorner⁷, Mario H. Cardiel⁸, Ian N. Bruce⁹, Elisa Gomez¹⁰, Amy M. DeLozier¹⁰, Jonathan Janes¹⁰, Matthew D Linnik¹⁰, Stephanie de Bono¹⁰, Maria E. Silk¹⁰ and Robert W. Hoffman¹⁰, ¹Cedars-Sinai Medical Center/David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of California at San Diego School of Medicine, La Jolla, CA, ⁵University of Pisa, Pisa, Italy, ⁶Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Charité Universitätmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ⁸Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, ⁹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁰Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (Bari), an oral selective inhibitor of Janus kinase (JAK)1 and JAK2, has been approved for the treatment of RA in the Europe and…
Abstract Number: 971 • 2018 ACR/ARHP Annual Meeting
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Mary A. Dooley¹, Gerald B. Appel², Richard Furie³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Ayanbola Elegbe¹⁰, David Jayne¹¹ and Michael A. Maldonado¹⁰, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Columbia University Medical Center, New York, NY, ³Northwell Health, New York, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Nephrology Division, Hospital Fernández, Buenos Aires, Argentina, ⁷Division of Rheumatology, University of Padova, Padova, Italy, ⁸Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Bristol-Myers Squibb, Princeton, NJ, ¹¹University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The tenets of novel treatment (tx) strategies for active class III/IV lupus nephritis (LN) aim to improve renal response rates, decrease extra-renal SLE disease…
Abstract Number: 972 • 2018 ACR/ARHP Annual Meeting
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Joan T. Merrill¹, Diane E. Shevell², Dominique Duchesne², Miroslawa Nowak², Sudeep Kundu², Ihab G. Girgis², Yanhua Sarah Hu², Steven G. Nadler³, Subhashis Banerjee² and John Throup², ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol-Myers Squibb, Princeton, NJ, ³Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The T cell costimulatory molecule, CD28, is critical for the activation of pathogenic T cells in autoimmune diseases.1,2 An anti-CD28 domain antagonist antibody, lulizumab…
Abstract Number: 973 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
Xiaona Jing¹, Chong Gao², Liran Hao¹, Meihua Hao¹, Zhaoyun Liang¹, Xiao-Feng Li³ and Junwei Chen¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose:To observe the clinical effect of low-dose IL-2 combined with rapamycin on the balance of Th17/Treg cells and on remission of patients with refractory SLE.…
Abstract Number: 974 • 2018 ACR/ARHP Annual Meeting
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial
Qiong Fu¹, Liangjing Lu¹, Jianhua Xu², Lie Dai³, Li Zhijun⁴, Lan He⁵, Xiaochun Zhu⁶, Lingyun Sun⁷ and Chunde Bao¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui Medical University, Hefei, China, ³Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁵Department of Rheumatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China, ⁶Rheumatology Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁷the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Previous studies have compared mycophenolate mofetil (MMF) and azathioprine (AZA) as maintenance therapy of lupus nephritis(LN). Leflunomide(LEF) is an immunosuppressive agent widely used in…
Abstract Number: 975 • 2018 ACR/ARHP Annual Meeting
Alteration of Vascular Inflammatory Markers in SLE By Anifrolumab in the Phase IIb Muse Study
KA Casey¹, WI White¹, Nickie L. Seto², Martin Playford³, MA Smith¹, P Carlucci², B Yu⁴, L Wang⁵, G Illei⁴, Nehal Mehta³ and Mariana J. Kaplan², ¹MedImmune, Gaithersburg, MD, ²NIAMS, Bethesda, MD, ³NHLBI, Bethesda, MD, ⁴MedImmune, Gaithersberg, MD, ⁵AstraZeneca, Gaithersburg, MD
Background/Purpose: Cardiovascular disease is a leading cause of death for patients with systemic lupus erythematosus (SLE), and the disease is widely known to feature premature…
Abstract Number: 976 • 2018 ACR/ARHP Annual Meeting
Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values
Fiona Niddrie¹, Gabor Major^2,3, Angela Myles^4,5, Davinder Singh-Grewal^6,7 and Jeffery Chaitow^6,7, ¹Rheumatology, Bone and Joint Institute, John Hunter Hospital, Hunter New England Local Health District, Newcastle, Australia, ²Rheumatology, Bone and Joint Institute, John Hunter Hospital, Newcastle, Australia, ³University of Newcastle, Newcastle, Australia, Newcastle, Australia, ⁴HNEkidshealth, Hunter New England Local Health District, Newcastle, Australia, ⁵Transition Care Network, Agency for Clinical Innovation, Sydney, Australia, ⁶Paediatric Rheumatology, John Hunter Hospital, Newcastle, Australia, ⁷Rheumatology, Sydney Children's Hospital Network, Randwick and Westmead, Australia
Background/Purpose: The transfer from the supportive and guided environment of paediatric to adult care with its increased emphasis on autonomy and self reliance poses challenges…
Abstract Number: 977 • 2018 ACR/ARHP Annual Meeting
Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies
Andrew Fell¹, Emma Carson¹, Gillian Coyle¹, Neil Martin¹, Jo Walsh¹ and Janet Gardner-Medwin², ¹Paediatic Rheumatology, Royal hospital for Children, Glasgow, United Kingdom, ²School of Medicine, Dentistry & Nursing, Child Health, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Original Reference Product (ORP) Infliximab lost market exclusivity in europe in early 2015. The Scottish National Health service (SNHS), runs a national procurement system…
Abstract Number: 978 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis
Gerd Horneff¹, Ivan Foeldvari², Ralf Trauzeddel³, Toni Hospach⁴, Kirsten Minden⁵, Hans-Iko Huppertz^6,7 and Ariane Klein⁸, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Hamburger Zentrum fur, Kinder-und Jugendrheumatologie, Hamburg, Germany, ³Helios Clinics, Berlin, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Prof Hess Clinic, Bremen, Germany, ⁷Prof. Hess Childrens Hospital, Bremen, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most prevalent chronic diseases of childhood and adolescence. Evidence suggests that early effective treatment is important…
Abstract Number: 979 • 2018 ACR/ARHP Annual Meeting
Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?
Daniel B. Horton^1,2, Jomaira Salas³, Aleksandra Wec⁴, Timothy Beukelman⁵, Alexis Boneparth⁶, Jaime Guzman⁷, Ky Haverkamp⁸, Melanie Kohlheim⁹, Melissa L. Mannion⁵, Nandini Moorthy¹, Elizabeth Stringer¹⁰, Lori Tucker⁷, Sarah Ringold¹¹ and Marsha Rosenthal², ¹Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ³Department of Sociology, Rutgers, the State University of New Jersey, New Brunswick, NJ, ⁴Mathematica Policy Research, Princeton, NJ, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatrics, Columbia University Medical Center, New York, NY, ⁷Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁸Family Medicine, University of Washington School of Medicine, Seattle, WA, ⁹Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁰IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ¹¹Pediatrics, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Prior research has focused on factors important to clinicians in decisions about withdrawing JIA therapy. Based on recent interviews with patients and caregivers about…
Abstract Number: 980 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort
Mia Glerup¹, Peter Stoustrup², Louise Hauge Matzen³, Veronika Rypdal^4,5, Ellen Nordal^5,6, Paula Frid^5,7, Ellen Dalen Arnstad^8,9, Marite Rygg^10,11, Olafur Thorarensen¹², Maria Ekelund^13,14, Lillemor Berntson¹⁵, Anders Fasth¹⁶, Håkan Nilsson¹⁷, Suvi Peltoniemi¹⁸, Kristiina Aalto¹⁸, Sirpa Arte¹⁹, Peter Toftedal²⁰, Susan Nielsen²⁰, Sven Kreiborg²¹, Troels Herlin²² and Thomas Klit Pedersen^23,24, ¹Department of Pediatrics, Dept. of Pediatrics, Aarhus University Hospital, Denmark, Aarhus, Denmark, ²Section of Orthodontics, Section of Orthodontics, Aarhus University, Denmark, Aarhus, Denmark, ³Department of Oral Radiology, Dept. of Oral Radiology, Aarhus University, Denmark, Aarhus, Denmark, ⁴Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁵Department of Clinical Medicine, Dept. of Clin. Med, UIT The Arctic University of Norway, Tromsø, Norway, ⁶Departments of Pediatrics, Dept. of Pediatrics, University Hospital of North Norway, Tromsø, Norway, ⁷Division of Oral and Maxillofacial Surgery, ENT-Dept. and Division of Oral and Maxillofacial Surgery, University Hospital North Norway and Public Dental Service Competence Centre of North Norway, Tromsø, Norway, ⁸Dep. Clin. and Mol. Med, Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ⁹Department of Pediatrics, Dept. of Pediatrics, Levanger Hospital, Nord-Trøndelag, Norway, Trondheim, Denmark, ¹⁰Department of Pediatrics, Dept. of Pediatrics, St. Olavs Hospital, Norway, Trondheim, Norway, ¹¹Dep. Clin. and Mol. Med., Dept. Clin. and Mol. Med., NTNU, Norway, Trondheim, Norway, ¹²Dep. of oral and Craniomaxillofacial surgery, Dept. of oral and Craniomaxillofacial surgery, St. Olavs Hospital, Norway, NTNU, Trondheim, Norway, ¹³Department of Pediatrics, Dept. of Pediatrics, Ryhov County Hospital, Jonkoping, Sweden, Jonkoping, Sweden, ¹⁴Uppsala University, Uppsala, Sweden, Jonkobing, Sweden, ¹⁵Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁶Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ¹⁷Department of Oral and Maxillofacial Surgery, Dept. of Oral and Maxillofacial Surgery, The Institute for Postgraduate Dental Education, Jönköping, Sweden, Jonkoping, Sweden, ¹⁸Hospital for Children and Adolescents, University of Helsinki, Finland, Helsinki, Finland, ¹⁹Dept. of Oral and Maxillofacial Diseases, University of Helsinki, Finland, Helsinki, Finland, ²⁰Department of Pediatrics, Dept. of Pediatrics, Copenhagen University Hospital, Denmark, Copenhagen, Denmark, ²¹Dept. of Paediatric Dentistry and Clinical Genetics, University of Copenhagen, Denmark, Copenhagen, Denmark, ²²Dept. of Pediatrics, Aarhus University Hospital, Aarhus N, Denmark, ²³Dept. of Oral and Maxillofacial Surgery, Aarhus University Hospital, Aarhus, Denmark, ²⁴Section of Orthodontics, Aarhus University, Denmark, Aarhus, Denmark
Background/Purpose: Involvement of the temporomandibular joint (TMJ) is a common finding in patients with juvenile idiopathic arthritis (JIA), but the long-term outcome in a non-selected…
Abstract Number: 981 • 2018 ACR/ARHP Annual Meeting
New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis
Esi Morgan¹, Alessandro Consolaro², Jane Munro³, Jennifer Horonjeff⁴, Brian M. Feldman⁵, Hayyah Clairman⁶, Clifton O. Bingham III⁷, Alessandra Alongi⁸, Vibeke Strand⁹, Marion A.J. van Rossum¹⁰, Richard Veselý¹¹, Hermine I. Brunner¹², Daniel Horton¹³, Daniel J Lovell¹⁴, Sarah Ringold¹⁵, Nicola Ruperto¹⁶, Suzanne Schrandt¹⁷, Natalie Jane Shiff¹⁸, Karine Toupin-April¹⁹ and Beverly Shea²⁰, ¹University of Cincinnati, Cincinnati, OH, ²Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ³Paediatric Rheumatology, Royal Children's Hospital, Victoria, Australia, ⁴Columbia University Medical Centre, New York, NY, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, ON, Canada, ⁷Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸University of Genova, Genova, Italy, ⁹Stanford University, Palo Alto, CA, ¹⁰Amsterdam Rheumatology and Immunology Center / Reade, Emma Children’s Hospital Amsterdam Medical Center, Amsterdam, Netherlands, ¹¹Scientific and Regulatory Management Department, European Medicines Agency, London, United Kingdom, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ¹⁶Universita di Genova Pediatria II, Genova, Italy, ¹⁷Arthritis Foundation, Saint Paul, MN, ¹⁸Pediatrics, University of Florida, Gainesville, FL, ¹⁹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ²⁰Bruyere Research Institute, Ottawa, ON, Canada
Background/Purpose: The current JIA Core Set (ACR Pediatric 30) to assess efficacy of medications in randomized controlled trials (RCTs) was published in 1997 and developed…
Abstract Number: 982 • 2018 ACR/ARHP Annual Meeting
In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells
Kojiro Sato, Yoshimi Aizaki, Hiroaki Yazawa and Toshihide Mimura, Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease, the cause of which is largely unknown. AOSD has been recently classified as one of…
Abstract Number: 983 • 2018 ACR/ARHP Annual Meeting
A MAPK Activated Kinase 2 Inhibitor Attenuates Inflammatory and Destructive Arthritis in Human Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Anders Mellemkjær³, Morten Aagaard Nielsen⁴, Line Dam Heftdal², Marie Iversen³, Peter Schafer⁵ and Bent Deleuran², ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Aarhus University, Aarhus, Denmark, ⁴Of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Celgene Corporation, Summit, NJ
Background/Purpose: Targeting intracellular pathways with oral small molecules is an attractive therapeutic approach for treating immune mediated inflammatory diseases. The mitogen-activated protein kinase (MAPK) pathway…
Abstract Number: 984 • 2018 ACR/ARHP Annual Meeting
Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus
Keiko Yoshimoto¹, Katsuya Suzuki¹, Shuntaro Saito², Jun Kikuchi¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Fractalkine (FKN, CX3CL1) and its receptor, CX3CR1, play an important role in chemotaxis of immune cells, such as cell adhesion, migration and infiltration into…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].